pharmaphorum July 16, 2024
Novo Nordisk’s parent company, Novo Holdings, has led a $100 million third-round financing for Swiss biotech Asceneuron, which is developing a non-amyloid therapy for Alzheimer’s disease.
The new funds will be used for mid-stage clinical trials of ASN51, an oral small-molecule inhibitor of O-GlcNAcase (OGA), which has emerged in recent years as a possible target for the treatment of tauopathies, including Alzheimer’s.
Studies have shown that OGA inhibitors promote the glycosylation of tau protein, which clumps together to form tangles in Alzheimer’s in a manner similar to the aggregation of amyloid into plaques.
OGA inhibitors promote glycosylation of tau, which seems to prevent aggregation and stabilise the protein in a soluble, non-pathogenic form. Tau tangles are also a feature of...
Today's Sponsors
Today's Sponsor